ArticleCureus2026
Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) in patients with end-stage renal disease (ESRD) requiring hemodialysis presents numerous challenges to clinicians, including selection of appropriate chemotherapy agents, safe dose adjustment, and supportive care management. Due to the lack of prospective studies in patients undergoing dialysis, it is difficult to determine the optimal therapeutic approach for this population. These patients are commonly excluded from large-scale AML clinical trials, which further complicates the determination of effective management strategies and associated toxicities. We present the case of a 51-year-old man with ESRD on hemodialysis who developed an adverse-risk AML (characterized by a BCL6 corepressor (BCOR) mutation with runt-related transcription factor 1 (RUNX1) and nuclear receptor-binding SET domain protein 1 (NSD1) abnormalities). Initial presentation was notable for profound pancytopenia without circulating blasts, although peripheral blood flow cytometry confirmed AML. Management required a multidisciplinary discussion with leukemia specialists, nephrology, and pharmacy. The patient was treated with azacitidine and venetoclax rather than intensive induction chemotherapy because of dialysis dependence, cardiovascular comorbidities, and anticipated toxicity. Azacitidine was administered after dialysis sessions, while venetoclax dosing was adjusted because of concomitant posaconazole prophylaxis. Repeat molecular testing no longer detected previously identified BCOR and RUNX1 abnormalities, although a persistent NSD1 variant remained detectable, and molecular remission could not be confirmed. Treatment was successfully continued through 12 cycles without clinically significant tumor lysis syndrome. Approximately one year after diagnosis, relapsed AML was identified on peripheral blood flow cytometry. This case highlights the feasibility of venetoclax-based lower-intensity therapy in selected dialysis-dependent AML patients while underscoring the persistent therapeutic limitations and adverse prognosis associated with relapsed disease in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.